Tolerance Bio, Inc.
PrivateLast Round
Early Stage
VC
Jun 18, 2026
Total Funding Raised
$20.2M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Tolerance Bio, Inc. is a biopharmaceutical company developing therapies focused on manipulating immune tolerance via the thymus to address various immune-mediated diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B2C
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tolerance Bio, Inc. Comparables
Compare Tolerance Bio, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Thymmune Therapeutics | 90% | |
| TECregen | 76% | |
| Sumitomo Pharma Co., Ltd. | 73% |
Tolerance Bio, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Stage VC | Jun 18, 2026 | ||||
| Seed | Dec 19, 2024 |
Key People
Founding team and executive leadership
Tolerance Bio, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Pacific 8 Ventures | Seed |
| Benjamin Franklin Technology Partners | Seed |
| Sessa Capital | Seed |
| BioAdvance Capital | Seed |
| Criteria Capital Risc | Seed |
| Columbus Venture Partners | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
$15.1M raised in an early stage VC round.
- Dec 19, 2024
$20M round led by Columbus Venture Partners.
Recent news
Latest coverage and updates
- partners_withAug 20, 2026
Tolerance Bio, Inc. partnered with NeoImmuneTech, Inc. on Aug 20th '26.
Tolerance Bio, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Tolerance Bio, Inc.'s valuation, stock price, and market status.
Is Tolerance Bio, Inc. a public or private company?
Tolerance Bio, Inc. is a private company.
What is the current stock price of Tolerance Bio, Inc.?
Tolerance Bio, Inc. is a private company with no public stock price. No recent secondary market data is available.
How much is Tolerance Bio, Inc. worth (valuation)?
Valuation information for Tolerance Bio, Inc. is not publicly available.
Can I buy Tolerance Bio, Inc. stock?
Tolerance Bio, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Tolerance Bio, Inc.'s last funding round?
Tolerance Bio, Inc.'s most recent funding round was Early Stage VC on June 18, 2026.
Who are the main investors in Tolerance Bio, Inc.?
Key investors in Tolerance Bio, Inc. include Columbus Venture Partners.
Will Tolerance Bio, Inc. IPO soon?
No public IPO plans have been announced for Tolerance Bio, Inc..
How can I track Tolerance Bio, Inc. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Tolerance Bio, Inc.'s secondary market activity and sign up for updates.